Femasys Inc. (NASDAQ:FEMY) Receives $5.50 Average Price Target from Analysts

Femasys Inc. (NASDAQ:FEMY) has received a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $5.50.

Several research analysts have commented on the company. Wall Street Zen downgraded Femasys from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Laidlaw began coverage on Femasys in a report on Thursday, November 20th. They issued a “buy” rating and a $6.50 target price on the stock. Lake Street Capital initiated coverage on shares of Femasys in a research report on Tuesday. They set a “buy” rating and a $1.50 target price for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Femasys in a research report on Thursday, January 22nd.

Femasys Price Performance

FEMY stock opened at $0.53 on Tuesday. The company has a market capitalization of $30.88 million, a P/E ratio of -0.73 and a beta of -2.53. The company has a fifty day moving average price of $0.57 and a 200-day moving average price of $0.62. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.61 and a current ratio of 1.16. Femasys has a 52-week low of $0.31 and a 52-week high of $1.76.

Institutional Trading of Femasys

Institutional investors have recently bought and sold shares of the company. Kovack Advisors Inc. bought a new position in shares of Femasys in the 4th quarter worth about $27,000. Osaic Holdings Inc. acquired a new stake in Femasys during the second quarter worth approximately $45,000. HRT Financial LP bought a new stake in Femasys in the fourth quarter worth approximately $30,000. Cetera Investment Advisers acquired a new position in Femasys in the fourth quarter valued at approximately $36,000. Finally, State Street Corp boosted its holdings in shares of Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after buying an additional 24,500 shares in the last quarter. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.